pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2005-0-1-93-102pulmo-2040Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL STUDIESКачество жизни больных хронической обструктивной болезнью легких в России: результаты многоцентрового популяционного исследования «ИКАР-ХОБЛ»Quality of life in chronic obstructive pulmonary disease patients in Russia: results of “IKAR-COPD” multi-center population-based studyЧучалинА. Г.ChuchalinA. G.БелевскийА. С.BelevskyA. S.ЧернякБ. А.ChernyakB. A.АлексееваЯ. Г.AlexeevaYa. G.ТрофименкоИ. Н.TrofimenkoI. N.ЗайцеваA. C.ZaitsevaA. S.НИИ пульмонологии МЗ и СР РФRussian FederationИркутский институт усовершенствования врачейRussian FederationГУЗ Отделенческая клиническая больница ст. Волгоград-1Russian Federation2005280220050193102Copyright © Чучалин А.Г., Белевский А.С., Черняк Б.А., Алексеева Я.Г., Трофименко И.Н., Зайцева A.C., 20052005Чучалин А.Г., Белевский А.С., Черняк Б.А., Алексеева Я.Г., Трофименко И.Н., Зайцева A.C.Chuchalin A.G., Belevsky A.S., Chernyak B.A., Alexeeva Y.G., Trofimenko I.N., Zaitseva A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/2040

Целью исследования «ИКАР-ХОБЛ» было изучение влияния хронической обструктивной болезни легких (ХОБЛ) и тактики ее лечения на качество жизни (КЖ) больных. Многоцентровое популяционное исследование проведено в 10 регионах РФ. В него были включено 702 пациента с ХОБЛ в возрасте от 40 до 85 лет: 18,5 % пациентов — с I стадией, 20,7 % – со II стадией, 40,9 % – с III стадией и 19,9 % – с IV стадией ХОБЛ (по критериям GOLD, 2003). Исследование КЖ проводилось с использованием общего «Краткого вопросника оценки статуса здоровья» (официального русскоязычного аналога вопросника MOS SF-36), и русскоязычной версии «Респираторного вопросника госпиталя Святого Георгия» – St. George’s Respiratory Questionnaire (SGRQ). Выявлено, что ХОБЛ оказывает выраженное негативное воздействие на КЖ пациентов, в первую очередь на их физический статус. Выраженность отклонений определяется степенью тяжести ХОБЛ, возрастом пациентов, длительностью заболевания, индексом курения.

The objective of the “IKAR-COPD” study was to evaluate quality of life in COPD patients with different treatment regimens. This multi-center population-based study was performed in 10 regions of Russia, 702 COPD patients aged 40 to 85 yrs were included in this study: 18.5 % with COPD stage I, 20.7 % with COPD stage II, 40.9 % with COPD stage III and 19.9 % with COPD stage IV (according to the GOLD 2003 criteria). The official Russian versions of the MOS SF-36 questionnaire and the St. George’s Respiratory Questionnaire (SGRQ) were used as generic and disease-specific health-related measures of quality of life. COPD significantly impaired the patients’ quality of life, mostly their physical activity. The quality of life depended on severity of COPD, a patient’s age, duration of the disease and smoking history.

ReferencesWorld Health Organization. World health report. Geneva: World Health Organization; 2000.World Health Organization. World health report. Geneva: World Health Organization; 2000.Carrozzi L., Rijcken B., Burney P. et al. Family history for chronic lung diseases and epidemiological determinants of COPD in the three European countries. Eur. Respir. Rev. 2001; 11 (80): 49—54.Carrozzi L., Rijcken B., Burney P. et al. Family history for chronic lung diseases and epidemiological determinants of COPD in the three European countries. Eur. Respir. Rev. 2001; 11 (80): 49—54.Lundbäck B., Viegi G., Jönsson E. et al. Bronchitis symptoms in Italy and Sweden — prevalence and risk factors. Eur. Respir. Rev. 2001; 11 (80): 55—64.Lundbäck B., Viegi G., Jönsson E. et al. Bronchitis symptoms in Italy and Sweden — prevalence and risk factors. Eur. Respir. Rev. 2001; 11 (80): 55—64.Nationale Heart, Lung, and Blood Institute. Morbidity & mortality: charbook on cardiovascular, lung, and blood diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 1998. Available from: URL: www.Nhlbi.nih.gov/nhlbi/seiin/other/cht-book/thm.Nationale Heart, Lung, and Blood Institute. Morbidity & mortality: charbook on cardiovascular, lung, and blood diseases. Bethesda, MD: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 1998. Available from: URL: www.Nhlbi.nih.gov/nhlbi/seiin/other/cht-book/thm.British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary desease. The COPD Guidelines Group of the Standards of Care Committee of BTS. Thorax 1997; 52 (suppl. 5): S1—S28.British Thoracic Society. BTS guidelines for the management of chronic obstructive pulmonary desease. The COPD Guidelines Group of the Standards of Care Committee of BTS. Thorax 1997; 52 (suppl. 5): S1—S28.Agusti A.G.N., Noguera A., Sauleda J. et al. Systemic effects of chronic obstructive pulmonary desease. Eur. Respir. J. 2003; 21: 347—360.Agusti A.G.N., Noguera A., Sauleda J. et al. Systemic effects of chronic obstructive pulmonary desease. Eur. Respir. J. 2003; 21: 347—360.Curtis J.R., Patrick D.L. The assessment of health sta tus among patients with COPD. Eur. Respir. J. 2003; 21 (suppl. 41): 36s—45s.Curtis J.R., Patrick D.L. The assessment of health sta tus among patients with COPD. Eur. Respir. J. 2003; 21 (suppl. 41): 36s—45s.Pauwells R.A., Buist S., Calverley P.M.A. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary desease. Am. J. Respir. Crit. Care Med. 2001; 163: 1256-1276.Pauwells R.A., Buist S., Calverley P.M.A. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary desease. Am. J. Respir. Crit. Care Med. 2001; 163: 1256-1276.Ware J.E. SF-36 Health Survey. Manual and interpretation guide. Second printing. Boston, Massachusetts: The Health Institute. New England Medical Center; 1997.Ware J.E. SF-36 Health Survey. Manual and interpretation guide. Second printing. Boston, Massachusetts: The Health Institute. New England Medical Center; 1997.Jones P.W., Quirk F.H., Baveystock C.M. The St.George’s respiratory questionnaire. Respir. Med. 1991; 85 (suppl. B): 25—31.Jones P.W., Quirk F.H., Baveystock C.M. The St.George’s respiratory questionnaire. Respir. Med. 1991; 85 (suppl. B): 25—31.Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatator on the rate of decline of FEV1. The Lung Health Study. J.A.M.A. 1994; 272: 1497— 1505.Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilatator on the rate of decline of FEV1. The Lung Health Study. J.A.M.A. 1994; 272: 1497— 1505.Seemungal T.A., Donaldson G.C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1608—1613.Seemungal T.A., Donaldson G.C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1608—1613.Rice K.L., Rubins J.B., Lebahn F. et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomised trial. Am. J. Respir. Crit. Care Med. 2000; 162: 174—178.Rice K.L., Rubins J.B., Lebahn F. et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomised trial. Am. J. Respir. Crit. Care Med. 2000; 162: 174—178.Чучалина А.Г. (ред.) Качество жизни у больных бронхиальной астмой и хронической обструктивной болезнью легких. М.: Атмосфера; 2004.Чучалина А.Г. (ред.) Качество жизни у больных бронхиальной астмой и хронической обструктивной болезнью легких. М.: Атмосфера; 2004.Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819—1823.Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819—1823.Burge P.S., Calverley P.M., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297—1303.Burge P.S., Calverley P.M., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320: 1297—1303.

The authors declare that there are no conflicts of interest present.